GSK trial proves RSV vaccine efficacy after three full seasons
(Alliance News) - GSK PLC on Tuesday said its Arexvy treatment was effective in treating patients suffering from a deadly respiratory virus with underlying medical conditions, paving the way for increased protection. Read More